{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-156660","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.973752+00:00","generated_at":"2026-06-01T05:34:04.742556+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galera Therapeutics eliminates COO role; stock moves to OTC Pink","bullets":["COO Robert Beardsley's position eliminated June 4, 2024 to reduce costs.","Company continues comprehensive review of strategic alternatives.","Beardsley eligible for severance; expects consulting at ~$400/hour.","Common stock now quoted on OTC Pink (GRTX); Nasdaq trading suspended."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-156660","json":"https://secwatch.observer/filing/0001193125-24-156660.json","markdown":"https://secwatch.observer/filing/0001193125-24-156660.md","text":"https://secwatch.observer/filing/0001193125-24-156660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/0001193125-24-156660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/d472894d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:34:04.742556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"609219d46b","claim":"Robert A. Beardsley departed as Chief Operating Officer at Galera Therapeutics, Inc..","evidence_excerpt":"On June 4, 2024, Galera Therapeutics, Inc. (the “Company”) notified Robert A. Beardsley, Ph.D., the Company’s Chief Operating Officer, that his position is being eliminated in order to save costs as the Company continues to undertake a comprehensive review of strategic alternatives for both the Company and its portfolio of dismutase mimetics.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524156660/0001193125-24-156660-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"position eliminated"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}